Brief: Tetra Bio-Pharma Provides Additional Information On Qixleef Following Letter Of Advice & Type B Meeting With U.S. FDA
24/02/2020 13:13
Feb 24 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIO-PHARMA PROVIDES ADDITIONAL INFORMATION ON
QIXLEEF
FOLLOWING LETTER OF ADVICE & TYPE B MEETING WITH USA FDA
* TETRA BIO PHARMA INC - QIXLEEF GLOBAL MARKET IS EXPANDED
TO
INCLUDE NONCANCER PAIN INDICATIONS.
* TETRA BIO PHARMA INC - SCIENTIFIC APPROACH TO QUALITY
CONTROL OF
QIXLEEF VALIDATED BY FDA.
Source text for Eikon: ID:nGNXbbBcr9
Further company coverage: TBP.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding